Form 4: Immunovant Director Robert Susman Reports Stock and Option Grants

Director Robert Graham Susman reports the acquisition of restricted stock units and stock options in Immunovant, Inc.

Summary

• Robert Graham Susman, a director of Immunovant, Inc., reported changes in beneficial ownership on May 1, 2025.
• Susman acquired 25,016 shares of common stock in the form of restricted stock units (RSUs).
• These RSUs were granted under the Issuer's 2019 Equity Incentive Plan and will vest in three equal annual installments starting May 1, 2025, contingent upon continuous service.
• Susman also acquired options to purchase 35,234 shares of common stock at an exercise price of $15.90.
• These options, also granted under the 2019 Equity Incentive Plan, will vest in three equal annual installments beginning May 1, 2025, contingent upon continuous service.
• Following these transactions, Susman directly owns 25,016 shares of common stock and options for 35,234 shares.

Sentiment

Score: 7

Explanation: The document reflects a standard equity grant, which is generally viewed positively as it aligns management interests with shareholders. There are no indications of negative news or concerns.

Positives

• The grant of RSUs and stock options to a director aligns their interests with those of the shareholders.
• The vesting schedule encourages continued service to the company.

Future Outlook

The vesting of the RSUs and stock options is contingent upon the Reporting Person's continuous service to the Issuer.

Industry Context

This is a standard practice for incentivizing and retaining key personnel in publicly traded companies, particularly in the biotechnology sector.

Comparison to Industry Standards

• Equity compensation is a common practice in the biotech industry to attract and retain talent.
• Vesting schedules are typically structured over a 3-4 year period, aligning with industry norms.
• Companies like Amgen, Regeneron, and Biogen also utilize similar equity incentive plans for their executives and directors.

Stakeholder Impact

• Shareholders may view the equity grants positively as they incentivize the director to work towards increasing shareholder value.
• Employees may see this as a positive sign of the company's commitment to its leadership.

Key Dates

Keywords

Immunovant, Director, Stock Options, RSUs, Beneficial Ownership, Form 4, IMVT, Equity Incentive Plan